- Home
- ACAD vs DLO Comparison
ACAD vs DLO Comparison
Compare ACAD & DLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- DLO
- Stock Information
- Founded
- ACAD 1993
- DLO 2013
- Country
- ACAD United States
- DLO Uruguay
- Employees
- ACAD N/A
- DLO N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- DLO Business Services
- Sector
- ACAD Health Care
- DLO Consumer Discretionary
- Exchange
- ACAD Nasdaq
- DLO Nasdaq
- Market Cap
- ACAD 2.5B
- DLO 2.5B
- IPO Year
- ACAD 2004
- DLO 2021
- Fundamental
- Price
- ACAD $22.71
- DLO $10.20
- Analyst Decision
- ACAD Buy
- DLO Buy
- Analyst Count
- ACAD 16
- DLO 9
- Target Price
- ACAD $27.00
- DLO $12.07
- AVG Volume (30 Days)
- ACAD 1.6M
- DLO 1.0M
- Earning Date
- ACAD 08-05-2025
- DLO 08-13-2025
- Dividend Yield
- ACAD N/A
- DLO 5.18%
- EPS Growth
- ACAD N/A
- DLO 9.51
- EPS
- ACAD 1.37
- DLO 0.48
- Revenue
- ACAD $996,283,000.00
- DLO $778,303,000.00
- Revenue This Year
- ACAD $13.39
- DLO $30.73
- Revenue Next Year
- ACAD $10.59
- DLO $26.54
- P/E Ratio
- ACAD $16.65
- DLO $21.10
- Revenue Growth
- ACAD 22.42
- DLO 11.59
- 52 Week Low
- ACAD $13.40
- DLO $6.58
- 52 Week High
- ACAD $25.23
- DLO $14.27
- Technical
- Relative Strength Index (RSI)
- ACAD 66.04
- DLO 48.45
- Support Level
- ACAD $21.35
- DLO $9.79
- Resistance Level
- ACAD $22.69
- DLO $10.38
- Average True Range (ATR)
- ACAD 0.76
- DLO 0.43
- MACD
- ACAD -0.13
- DLO -0.11
- Stochastic Oscillator
- ACAD 70.76
- DLO 38.76
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About DLO DLocal Limited
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables global enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.